Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Takeda
- Trial code
- NCT07299097
- Record updated
- 30 October 2026
- Original description
The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.Read full original descriptionShow less
The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.
Inclusion: Participants with NT1 or NT2 following International Classification of Sleep Disorders, 3rd Edition (ICSD-3) or ICSD-3 text revision (ICSD-3-TR) criteria who are alive at any point during 2023 or 2024; Any age, ethnicity and nationality; Treated / under follow-up in the study site and residing in the hospitals' reference areas. Consideration will be given if participants have changed their address or reached adulthood; Confirmation to have a diagnosis of NT1 or NT2 by a specialist; Participants greater than equal to (≥) 18 years or parents of narcolepsy participants under 18 years of age; Any gender, ethnicity or nationality; Residence in Spain.
Exclusion: NT1 or NT2 participants who do not reside in the hospitals' reference areas; Supplementary Group:; Participants without a confirmed NT1 or NT2 diagnosis by a specialist.
Core Group:.